|
|
 |
|
Viewing report
|
|
|
|
R&D Trends: Prostate Cancer - Newly approved therapies shift treatment dynamics for castrate-resistant disease
Datamonitor, June 2011, Pages: 31
Introduction
The late-phase prostate cancer pipeline is dominated by targeted therapies, closely followed by immunotherapies. There are a growing number of therapies with novel targets such as Zibotentan (AstraZeneca) which targets endothelin-A (ET-A). Identification of the correct molecular target will be key to ensuring that a novel drug is effective.
Features and benefits
- In-depth analysis of the prostate cancer pipeline – development stage, therapeutic class, molecular targets, and changes in pipeline since 2009
- In-depth analysis of current comparator therapy – target product profile, unmet needs, and innovative early-stage approaches
- In-depth analysis of clinical trial design – patient selection, duration, clinical endpoints, and future developments in trial design
- The future of prostate cancer treatment – improving biomarkers, and novel targeted therapies
Highlights
Targeted therapies dominate the prostate cancer pipeline. However, developers will face strong competition from recently approved therapies. The advancement in understanding the molecular basis of prostate cancer has exposed new targets, but companies must identify the correct ones to improve the chances of success.
Clinical trial design must demonstrate the clinical efficacy of novel therapies. The selection of correct patient populations, trial duration, and endpoints is becoming increasingly important in the era of target therapy development.
New therapies will have to focus on improving overall survival in advanced, castrate-resistant disease, particularly when other therapies have been exhausted. They must be superior to the current standard of care, Taxotere (docetaxel; Sanofi).
Your key questions answered
- Understand how the dynamics of prostate cancer treatment are changing as a result of newly emerging therapies
- Identify the target product profile for new therapies and innovative early-stage drug targets in relation to the current standard of care
- Assess the potential for new innovative approaches to treating prostate cancer and obstacles that may affect their development
|
|
|
|
